@dianaysufamiliade6's tirzepatide injection video, fact-checked

What does this video actually show?

@dianaysufamiliade6 demonstrates self-injecting tirzepatide (brand name Mounjaro or Zepbound) for weight loss in a TikTok that's got 18.7K views. She shows the injection process and mentions it's for weight reduction. The video includes paid partnership hashtags, suggesting potential sponsorship.

The creator doesn't make specific medical claims about effectiveness or dosing. She simply documents her personal experience with the injection process itself.

Is tirzepatide actually effective for weight loss?

Yes, clinical trial data shows substantial weight reduction. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found participants lost an average of 22.5% of their body weight on the highest 15mg dose over 72 weeks.

That's significantly more than semaglutide's results. The same study showed 15mg tirzepatide beat 2.4mg semaglutide head-to-head, with tirzepatide users losing about 7 percentage points more body weight.

Tirzepatide works by targeting both GLP-1 and GIP receptors, while semaglutide only hits GLP-1. This dual mechanism likely explains the superior weight loss numbers we're seeing in trials.

What injection details did she get right?

The video appears to show proper subcutaneous injection technique in what looks like the thigh or abdomen area. Both are FDA-approved injection sites for tirzepatide pens.

She's using what appears to be a pre-filled pen, which is the standard delivery method. The pen design makes self-injection relatively straightforward compared to drawing up medication from vials.

However, we can't verify her dosing from the video. Tirzepatide starts at 2.5mg weekly and can go up to 15mg, but there's no way to confirm what dose she's actually using.

What are the real risks she doesn't mention?

The SURMOUNT trials reported nausea in 84% of participants on the highest dose. That's not a minor side effect you can ignore. Vomiting affected 31% of people, and diarrhea hit 23%.

More concerning, the trials excluded people with eating disorders, severe gastroparesis, or inflammatory bowel disease. Real-world users might face different risk profiles than study participants.

Cost is another factor missing from her video. Without insurance coverage, tirzepatide runs about $1,000 monthly. The paid partnership hashtags make this omission particularly problematic.

What should you actually know before considering tirzepatide?

FDA approval covers tirzepatide for type 2 diabetes (Mounjaro) and obesity (Zepbound) in adults with BMI ≥30 or ≥27 with weight-related conditions. It's not approved for cosmetic weight loss in people with normal BMI.

Starting doses begin at 2.5mg weekly, escalating every 4 weeks based on tolerance. Most people don't jump straight to higher doses like some social media posts suggest.

The injection technique matters less than medical supervision. Regular monitoring for pancreatitis, gallbladder issues, and kidney problems is part of proper tirzepatide management that social media demos can't provide.